Travaux scientifiques

Doç. Dr. Mutlu Hızal

101 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Prognostic Importance of Albumin Globulin Ratio in Small Cell Lung Cancer

    Ankara Medical Journal, 2019

    DOI 10.17098/amj.651978 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  2. Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?

    PubMed, 2019

    PMID 31646779 2 citations (OpenAlex) Source : OpenAlex

  3. Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?

    Future Oncology, 2019

    DOI 10.2217/fon-2018-0503 PMID 30854890 Texte intégral en libre accèsSource : OpenAlex

  4. Bazal Hücreli Kanserde Güncel Tedavi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2019

    Source : OpenAlex

  5. EP1.04-17 The Association of Clinicopathologic Features and Peripheral Blood Parameters with High PD-L1 Expression in Non-Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2019

    DOI 10.1016/j.jtho.2019.08.2145 Texte intégral en libre accèsSource : OpenAlex

  6. Cilt Kanserleri

    AYBU AVESIS, 2019

    Source : OpenAlex

  7. Evaluation of dynamic serum thiol/disulfide homeostasis in locally advanced and metastatic gastric cancer

    Journal of Oncological Sciences, 2018

    DOI 10.1016/j.jons.2018.01.002 8 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  8. P2.01-83 Evaluation of Dynamic Thiol/Disulphide Homeostasis in Advance Non-Small Cell Lung Cancer and Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2018

    DOI 10.1016/j.jtho.2018.08.1137 Texte intégral en libre accèsSource : OpenAlex

  9. Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localization

    Journal of Cancer Research and Therapeutics, 2018

    DOI 10.4103/jcrt.jcrt_624_17 PMID 30880755 21 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  10. Mutational status of lung cancer patients and survival outcomes for patients with limited brain metastases.

    PubMed, 2018

    PMID 30722126 2 citations (OpenAlex) Source : OpenAlex

  11. Baş-Boyun Kanserlerinde Epidemiyoloji, Etiyoloji ve Evreleme

    Turkiye Klinikleri Medical Oncology - Special Topics, 2018

    Source : OpenAlex

  12. Lokal İleri ve Metastatik Baş-Boyun Kanserlerinde Sistemik ve Hedeflenmiş Tedaviler

    Turkiye Klinikleri Medical Oncology - Special Topics, 2018

    Source : OpenAlex

  13. Optimal Regimen For Treatment-Naive Hormone Receptor-Positive Her-2 Negative Metastatic Breast Cancer

    Future Oncology, 2018

    DOI 10.2217/fon-2018-0086 PMID 30484708 Texte intégral en libre accèsSource : OpenAlex

  14. Diffüz Büyük B Hücreli Lenfomalarda CD30 Ekspresyon Sıklığı ve Klinikopatolojik Veriler ile İlişkisi

    AYBU AVESIS, 2018

    Source : OpenAlex

  15. Efficacy of The Second-line Treatment in Metastatic Pancreas Cancer

    AYBU AVESIS, 2018

    Source : OpenAlex

  16. The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)

    Annals of Oncology, 2017

    DOI 10.1093/annonc/mdx366.001 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  17. The association and prognostic significance of programmed death-ligand 1 (PD-L1) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM) patients.

    Journal of Clinical Oncology, 2017

    DOI 10.1200/jco.2017.35.15_suppl.e13536 1 citation (OpenAlex) Source : OpenAlex

  18. Do all aromatase inhibitors have similar efficacy and safety?

    Future Oncology, 2017

    DOI 10.2217/fon-2017-0228 PMID 28831832 2 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

  19. Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer.

    Future Oncology, 2017

    DOI 10.2217/fon-2017-0270 PMID 28829190 8 citations (OpenAlex) Source : ORCID

  20. The current status of adjuvant treatment for high-risk renal cell carcinoma.

    Future Oncology, 2017

    DOI 10.2217/fon-2017-0352 PMID 28984480 Source : ORCID

  21. Ferritin: Is it a Predictor of Prognosis in Myelodysplastic Syndrome?

    The World Clinics Journal of Medical Sciences, 2017

    DOI 10.5336/worldclin.2017-56274 Texte intégral en libre accèsSource : OpenAlex

  22. The Role of Dynamic Serum Thiol-Disulphide Homeostasis in Metastatic Gastric Cancer

    AYBU AVESIS, 2017

    Source : OpenAlex

  23. glioBlastome multiforme hastalarında pd-l1, pd-1, tümör infiltre eden lenfosit ve ıdh-1 gen mutasyon varlığının prognostik öneminin değerlendirilmesi

    AYBU AVESIS, 2017

    Source : OpenAlex

  24. Glioblastome Multiforme Tanılı Hastalarda Eritrosit DağIlım Hacmi-Trombosit Oranının Sağ Kalım İle İlişkisi

    AYBU AVESIS, 2017

    Source : OpenAlex

  25. ERkEn EvRE koloREktal kanSERlERdE RdW-platElEt oRanInIn pRognoStik önEMi

    AYBU AVESIS, 2017

    Source : OpenAlex

  26. 2016 yIlInda tÜRkiyE kaynaklI onkolojik yayInlaR

    AYBU AVESIS, 2017

    Source : OpenAlex

  27. ilERi EvRE koloREktal kanSERlERdE RdW-platElEt oRanInIn pRognoStik önEMi

    AYBU AVESIS, 2017

    Source : OpenAlex

  28. The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)

    AYBU AVESIS, 2017

    Source : OpenAlex

  29. t790M MutaSyonu pozitiF akciğER kanSERindE oSiMERtiniB diREnci; olgu SunuMu

    AYBU AVESIS, 2017

    Source : OpenAlex

  30. Evaluation of dynamic serum thiol disulphide homeostasis in colorectal cancer

    AYBU AVESIS, 2017

    Source : OpenAlex

  31. MEtaStatik vE nEoadjuvant tEdavi alan tRanSizyonEl HÜcREli MESanE kanSERindE HuMan EquiliBRativE nuclEoSidE tRanSpoRtER 1 (HEnt1) MolEkÜlÜnÜn pREdiktiF vE pRognoStik önEMinin dEğERlEndiRilMESi

    AYBU AVESIS, 2017

    Source : OpenAlex

  32. kÜçÜk HÜcREli akciğER kanSERindE yEni pRogSnoStik BEliRtEç: alBuMin-gloBulin oRanI

    AYBU AVESIS, 2017

    Source : OpenAlex

  33. Compare tumor features and survival in right sided and left sided early stage colorectal cancer

    AYBU AVESIS, 2016

    Source : OpenAlex

  34. Effect of red cell disturbatıon width to platelet ratio on dısease free survival in early stage colorectal cancer

    AYBU AVESIS, 2016

    Source : OpenAlex

  35. Effects of neutrophil lymphocyte ratio and platelet lymphocyte ratio on survival of non metastatic colorectal cancer

    AYBU AVESIS, 2016

    Source : OpenAlex

  36. THE NEUTROPHIL LYMPHOC YTE RATIO MAY HAVE PROGNOSTICEFFECT IN THE METASTATIC COLORECTAL CANCER

    AYBU AVESIS, 2016

    Source : OpenAlex

  37. EFFECT OF RED CELL DISTURBATION WIDTH TO PLATELET RATIO ONDISEASE FREE SURVIVAL IN EARLY STAGE COLORECTAL CANCER

    AYBU AVESIS, 2016

    Source : OpenAlex

  38. THE PROGNOSTIC FACTORS IN STAGE 3 COLORECTAL CANCER PATIENTS

    AYBU AVESIS, 2016

    Source : OpenAlex

  39. Association between tumor localisation andClinicopathologic characteristics and survival of colorectal cancer

    AYBU AVESIS, 2016

    Source : OpenAlex

  40. Association between tumor localisation and clinicopathological characteristics and survival of colorectal cancer

    AYBU AVESIS, 2016

    Source : OpenAlex

  41. Metastatic colorectal cancer survival İs there a difference between synchronous or metachronous tumors

    AYBU AVESIS, 2016

    Source : OpenAlex

  42. A rare case metastatic anal cloacogenic transitional cell carcinoma

    AYBU AVESIS, 2016

    Source : OpenAlex

  43. METASTATIC COLORECTAL CANCER SURVIVAL IS THERE A DIFFERENCEBETWEEN SYNCHRONOUS OR METACHRONOUS TUMORS

    AYBU AVESIS, 2016

    Source : OpenAlex

  44. PROGNOSTIC IMPORTANCE RED CELL DISTURBATION WIDTH TOPLATELET RATIO IN ADVANCED COLORECTAL CANCER

    AYBU AVESIS, 2016

    Source : OpenAlex

  45. Gastric cancer with lung metastasis and concurrent miliary tuberculosis

    AYBU AVESIS, 2016

    Source : OpenAlex

  46. EFFECT OF THE RAS STATUS ON SURVIVAL IN ADVANCED COLON CANCER

    AYBU AVESIS, 2016

    Source : OpenAlex

  47. ASSESSMENT OF THE COST EFFECTIVENESS OF THE FIRST LINE TARGETED THERAPIES FOR ADVANCED COLON CANCER IN TURKEY

    AYBU AVESIS, 2016

    Source : OpenAlex

  48. ASSOSCIATION BETWEEN TUMOR LOCALISATION AND CLINICOPATHOLOGICAL CHARACTERISTICS AND SURVIVAL OF COLORECTAL CANCER

    AYBU AVESIS, 2016

    Source : OpenAlex

  49. Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?

    Clinical Rheumatology, 2015

    DOI 10.1007/s10067-014-2854-1 PMID 25597616 12 citations (OpenAlex) Source : ORCID

  50. AB0194 Ll-37: A New Marker for Interstitial Lung Disease (ILD) in Systemic Sclerosis (SSC)?

    Annals of the Rheumatic Diseases, 2014

    DOI 10.1136/annrheumdis-2014-eular.2948 1 citation (OpenAlex) Source : OpenAlex